Evidence map›Paper›PMID 37626874›Full record

ArticleCells2023

PM

Bhavana Sivakumar, Nemat Ali, Sheikh F Ahmad, Ahmed Nadeem, Mohammad Waseem, Gino A Kurian

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Bhavana SivakumarVascular Biology Laboratory, School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur 613401, Tamil Nadu, India.
Nemat AliDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0001-6525-4202
Sheikh F AhmadDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-8282-3726
Ahmed NadeemDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0003-2038-8367
Mohammad WaseemDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland Eastern Shore, Princess Anne, MD 21853, USA.ORCID 0000-0002-1708-0137
Gino A KurianVascular Biology Laboratory, School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur 613401, Tamil Nadu, India.ORCID 0000-0003-2051-2399
King Saud University · SASASTRA University · INUniversity of Maryland Eastern Shore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulatory GSK3β is recognized as a biomarker and therapeutic target for diseases, including myocardial diseases. However, its potential as a target for myocardial ischemia-reperfusion injury (IR) in the presence of PM

Indexed as

Myocardial Reperfusion InjuryAMP-Activated Protein KinasesAnimalsGlycogen Synthase Kinase 3 betaParticulate MatterPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRatsRats, WistarAMP-Activated Protein KinasesGlycogen Synthase Kinase 3 betaParticulate MatterPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktbiomarkercardiovascular diseasesdiesel particulate matterGSK 3βischemia-reperfusion injurymitochondriaPM2.5SB216763

Identifiers

PMID37626874
PMCPMC10453520
OpenAlexW4385835114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.